ライフサイエンスコーパス: circulating tumor cell

1 a metastatic niche that captures aggressive circulating tumor cells.

2 ly studied assays, circulating tumor DNA and circulating tumor cells.

3 ent manner, resulting in elevated numbers of circulating tumor cells.

4 were measured in blood, hair follicles, and circulating tumor cells.

5 te cancer, by greatly reducing the number of circulating tumor cells.

6 lls), metastatic prostate cancer lesions and circulating tumor cells.

7 lung but powerfully licenses colonization by circulating tumor cells.

8 c monitoring, most notably in the context of circulating tumor cells.

9 d 19%, respectively, had detectable AR-V7 in circulating tumor cells.

10 of prostate cancer from biopsy specimens and circulating tumor cells.

11 s to anoikis, thereby reducing the number of circulating tumor cells.

12 arkers, single-nucleotide polymorphisms, and circulating tumor cells.

13 changes in tumor burden, than did CA 15-3 or circulating tumor cells.

14 n of tumors and the colonization of lungs by circulating tumor cells.

15 iciently seed metastatic lesions than single circulating tumor cells.

16 n mice, but also to prevent the emergence of circulating tumor cells.

17 S) microfluidic channel for the detection of circulating tumor cells.

18 sociated with invasive cancer phenotypes and circulating tumor cells.

19 heterogeneity in tumors and analyzing single circulating tumor cells.

20 to be a vital trait of cancer cells such as circulating tumor cells, allowing them to undergo revers

21 Less circulating tumor cells along with reduction in malignan

22 d dynamic range for routine detection of PCa circulating tumor cells and can be adapted to detect oth

23 analysis in high cellular backgrounds (e.g., circulating tumor cells and fetal cells in maternal bloo

24 carcinoma cells reduced the number of viable circulating tumor cells and inhibited lung metastasis in

25 reduced tumor size as well as the number of circulating tumor cells and metastases in an orthotopic

26 cer following resection, elevated numbers of circulating tumor cells and more spontaneous metastases.

27 noikis enables them to disseminate as viable circulating tumor cells and seed distant organs.

28 mice inhibited extravasation/colonization of circulating tumor cells and significantly reduced metast

29 of commensal homeostasis results in enhanced circulating tumor cells and subsequent dissemination to

30 l assays of drug-target engagement in living circulating tumor cells and therefore have the potential

31 els, ADCC enhancement was crucial to deplete circulating tumor cells and to suppress metastases.

32 Circulating tumor cells and tumor-derived RNA in the blo

33 rovements in measurable soft tissue disease, circulating tumor cells, and bone biomarkers.

34 algesic use, measurable soft tissue disease, circulating tumor cells, and bone biomarkers.

35 ctive surveillance have evaluated microRNAs, circulating tumor cells, and exosomes.

36 re thus offers a unique route for separating circulating tumor cells, and for label-free cell separat

37 ormation of ascites, tumor burden over time, circulating tumor cells, and hepatic metastases.

38 on in the primary tumors, elevated levels of circulating tumor cells, and increased spontaneous metas

39 orphological differences among the parental, circulating tumor cells, and lung metastatic cells.

40 herringbone patterns suitable for capture of circulating tumor cells are made as a demonstrative appl

41 Circulating tumor cells are tumor-derived pioneers respo

42 of metastasis, detection and destruction of circulating tumor cells are vital for impeding metastasi

43 ing the extravasation process or re-entry of circulating tumor cells at metastatic sites.

44 Circulating tumor cell-based AR-V7 detection may serve a

45 We report that circulating tumor cells become trapped within NETs in vi

46 date by tumor recurrence as a consequence of circulating tumor cells before the surgery.

47 ed with metastases formation and presence of circulating tumor cells before therapy, whereas (iii) th

48 biomarker, expressed on prostate tissue and circulating tumor cells but also found in serum.

49 tinuous high-throughput selective capture of circulating tumor cells by dielectrophoresis at arrays o

50 Recent scientific advances in understanding circulating tumor cells, cell-free DNA/RNA, and exosomes

51 val outcomes was evaluated and compared with circulating tumor cells (CellSearch).

52 Circulating tumor cell clusters (CTC clusters) are poten

53 Circulating tumor cell clusters (CTC clusters) are prese

54 This result suggests that circulating tumor cell clusters might be able to better

55 Intriguingly, locally disseminated clusters, circulating tumor cell clusters, and lung micrometastase

56 , local dissemination, intravascular emboli, circulating tumor cell clusters, and micrometastases.

57 During cancer metastasis, circulating tumor cells constantly experience hemodynami

58 ine phosphatase level (r = 0.572, P < .001), circulating tumor cell count (r = 0.613, P = .004), and

59 hange in prostate-specific antigen level and circulating tumor cell count (r = 0.63 [95% CI: 0.27, 0.

60 ion with prostate-specific antigen level and circulating tumor cell count were assessed by using Spea

61 ntigen level or a confirmed reduction in the circulating tumor-cell count from 5 or more cells per 7.

62 ored, using individual patient data, week 13 circulating tumor cell (CTC) and prostate-specific antig

63 secondary tumor initiation largely depend on circulating tumor cell (CTC) and vascular endothelial ce

64 Given that previous reports suggested that circulating tumor cell (CTC) AR-V7 detection is a poor p

65 linical benefit from early taxane switch and circulating tumor cell (CTC) biomarkers to interrogate m

66 technique for improving immunoaffinity-based circulating tumor cell (CTC) capture by patterning regio

67 Circulating tumor cell (CTC) clusters have an enhanced c

68 Circulating tumor cell (CTC) detection offers various op

69 Conventional circulating tumor cell (CTC) detection strategies rely o

70 We evaluated circulating tumor cell (CTC) enumeration as a surrogate

71 Circulating tumor cell (CTC) enumeration has not been pr

72 the primary tumor vascular response and the circulating tumor cell (CTC) fraction derived from a tis

73 th PSA > 4.0 ng/mL, safety and tolerability, circulating tumor cell (CTC) levels, and seven plasma IG

74 om primary tumors are believed to facilitate circulating tumor cell (CTC) seeding of distant metastas

75 irculating cancer stem cells (CCSCs), a rare circulating tumor cell (CTC) type, recently arose as a u

76 Circulating tumor cell (CTC)-based liquid biopsies provi

77 Such restrictions limit the translation of circulating tumor cell (CTC)-based liquid biopsy assays

78 Multicellular aggregates of circulating tumor cells (CTC clusters) are potent initia

79 drug resistance-conferring gene mutations on circulating tumor cells (CTC) and cell-free circulating

80 The interaction between circulating tumor cells (CTC) and endothelial cells duri

81 This panel was also applied to circulating tumor cells (CTC) and provided evidence that

82 Most of the current strategies for detecting circulating tumor cells (CTC) are based on the epithelia

83 Circulating tumor cells (CTC) are shed in peripheral blo

84 ss the current and future potential of using circulating tumor cells (CTC) as a biomarker to assess s

85 Circulating tumor cells (CTC) disseminating is an import

86 EGFR expression was also observed in circulating tumor cells (CTC) during prostate cancer met

87 gital pathology features on 9,225 individual circulating tumor cells (CTC) from 179 unique metastatic

88 Molecular characterization of circulating tumor cells (CTC) from blood is technically

89 ), a technique previously used for isolating circulating tumor cells (CTC) from blood.

90 specific marker exists for the detection of circulating tumor cells (CTC) from different types of sa

91 Cancer stem-like cells (CSC) and circulating tumor cells (CTC) have related properties as

92 Circulating tumor cells (CTC) in blood are promising new

93 Circulating tumor cells (CTC) in the blood are hypothesi

94 Circulating tumor cells (CTC) in the peripheral blood co

95 Blood tests to detect circulating tumor cells (CTC) offer great potential to m

96 are launched into the bloodstream as single circulating tumor cells (CTC) or multicellular CTC clust

97 Circulating tumor cells (CTC) released into blood from p

98 We sought to develop a biomarker of CIN in circulating tumor cells (CTC) that are more likely to re

99 A method is presented for the detection of circulating tumor cells (CTC) using mass spectrometry (M

100 Further, both cCAF and circulating tumor cells (CTC) were significantly greater

101 Here, we evaluated whether circulating tumor cells (CTC) with aberrant ALK-FISH pat

102 o the primary tumor, their interactions with circulating tumor cells (CTC) within the bloodstream, an

103 mesenchymal transition (EMT) is prominent in circulating tumor cells (CTC), but how it influences met

104 arly detection of metastasis can be aided by circulating tumor cells (CTC), which also show potential

105 temic dissemination is most likely caused by circulating tumor cells (CTC).

106 al applications, most recently for isolating circulating tumor cells (CTC).

107 tection of circulating tumor DNA (ctDNA) and circulating tumor cells (CTC).

108 fective metastatic chemoprevention targeting circulating tumor cells (CTC).

109 tion of tumor cells in the peripheral blood (circulating tumor cells, CTC) and CSF (cerebrospinal flu

110 spot PIK3CA mutations (E545 K and H1047R) in circulating tumor cells (CTCs) and cell free DNA (cfDNA)

111 terature regarding two potential biomarkers, circulating tumor cells (CTCs) and cell-free DNA (cfDNA)

112 on the molecular information extracted from circulating tumor cells (CTCs) and circulating tumor DNA

113 based biopsies (BBBs), blood is purified for circulating tumor cells (CTCs) and clinical utility is t

114 ssess the prognostic and predictive value of circulating tumor cells (CTCs) and disseminated tumor ce

115 Circulating tumor cells (CTCs) and disseminated tumor ce

116 We determined the prevalence of circulating tumor cells (CTCs) and explored their utilit

117 Circulating tumor cells (CTCs) and plasma levels of Epst

118 y tumor growth but blocked the production of circulating tumor cells (CTCs) and the formation of lymp

119 Circulating tumor cells (CTCs) are a treasure trove of i

120 Circulating tumor cells (CTCs) are an important biomarke

121 Circulating tumor cells (CTCs) are cancer cells released

122 Circulating tumor cells (CTCs) are established cancer bi

123 Circulating tumor cells (CTCs) are exfoliated at various

124 Circulating tumor cells (CTCs) are important biomarkers

125 Circulating tumor cells (CTCs) are important targets for

126 Circulating tumor cells (CTCs) are of great interest in

127 Circulating tumor cells (CTCs) are of recognized importa

128 Circulating tumor cells (CTCs) are phenotypically hetero

129 Circulating tumor cells (CTCs) are present at low concen

130 Circulating tumor cells (CTCs) are promising biomarkers

131 Circulating tumor cells (CTCs) are rare cancer cells tha

132 Circulating tumor cells (CTCs) are shed from a solid tum

133 Circulating tumor cells (CTCs) are shed into the bloodst

134 Circulating tumor cells (CTCs) are shed into the bloodst

135 cusing microfluidic approaches in retrieving circulating tumor cells (CTCs) at single-cell resolution

136 Molecular analysis of circulating tumor cells (CTCs) at single-cell resolution

137 Detection of circulating tumor cells (CTCs) at the time of surgery ma

138 The methods for isolating rare cells such as circulating tumor cells (CTCs) can be generally classifi

139 Direct analysis of circulating tumor cells (CTCs) can inform on molecular m

140 Characterization of rare, heterogeneous circulating tumor cells (CTCs) can provide insight into

141 Circulating tumor cells (CTCs) contain metastatic precur

142 en receptor splice variant-7 (AR-V7) mRNA in circulating tumor cells (CTCs) correlated with poor outc

143 Circulating tumor cells (CTCs) derived from a primary tu

144 Anticancer drug efficacy has been tested on circulating tumor cells (CTCs) derived from patient bloo

145 Circulating tumor cells (CTCs) detection, enumeration an

146 Circulating tumor cells (CTCs) disseminate from the prim

147 We evaluated the prognostic impact of circulating tumor cells (CTCs) for patients with presume

148 tivator of NF-kappabeta (RANK) in individual circulating tumor cells (CTCs) from 40 late-stage (III-I

149 tion and rapid molecular characterization of circulating tumor cells (CTCs) from a liquid biopsy coul

150 deaths and it is fueled by the generation of circulating tumor cells (CTCs) from a primary tumor depo

151 Isolation of circulating tumor cells (CTCs) from blood samples has im

152 ole in human cancer, we characterized EMT in circulating tumor cells (CTCs) from breast cancer patien

153 e biomaterial for the capture and release of circulating tumor cells (CTCs) from cancer patient blood

154 thin the circulatory system, platelets guard circulating tumor cells (CTCs) from immune elimination a

155 ndrogen receptor splice variant 7 (AR-V7) in circulating tumor cells (CTCs) from men with castration-

156 llowed for detection and characterization of circulating tumor cells (CTCs) from patients with cancer

157 enable the detection and isolation of single circulating tumor cells (CTCs) from patients with prosta

158 Sensitive detection of circulating tumor cells (CTCs) from patients' peripheral

159 sitive and high-throughput method to analyze circulating tumor cells (CTCs) from peripheral blood.

160 e examined copy-number aberrations (CNAs) in circulating tumor cells (CTCs) from pretreatment SCLC bl

161 Isolation and analysis of circulating tumor cells (CTCs) from the blood of patient

162 lterations in single primary tumor cells and circulating tumor cells (CTCs) from the same patient.

163 The enumeration of EpCAM-positive circulating tumor cells (CTCs) has allowed estimation of

164 More recently, detection of circulating tumor cells (CTCs) has been considered as an

165 Evaluation of circulating tumor cells (CTCs) has demonstrated clinical

166 Enumeration of circulating tumor cells (CTCs) has proved valuable for e

167 The ability to isolate and analyze rare circulating tumor cells (CTCs) has the potential to furt

168 Circulating tumor cells (CTCs) have a great potential as

169 Circulating tumor cells (CTCs) have become an establishe

170 For example, circulating tumor cells (CTCs) have been demonstrated as

171 l as surface marker identification of single circulating tumor cells (CTCs) have been demonstrated.

172 Circulating tumor cells (CTCs) have been detected by us

173 Circulating tumor cells (CTCs) have been linked to cance

174 Although circulating tumor cells (CTCs) have potential as diagnos

175 Circulating tumor cells (CTCs) have the potential of bec

176 cance of disseminated tumor cells (DTCs) and circulating tumor cells (CTCs) in 1 cohort of patients w

177 Circulating tumor cells (CTCs) in blood are associated w

178 quantification and in situ identification of circulating tumor cells (CTCs) in blood are still elusiv

179 Circulating tumor cells (CTCs) in blood can provide valu

180 e (Fe(3)O(4)) nanoparticles (NPs) to capture circulating tumor cells (CTCs) in blood for head and nec

181 sensitive, selective, and rapid detection of circulating tumor cells (CTCs) in blood samples.

182 Presence and frequency of rare circulating tumor cells (CTCs) in bloodstreams of cancer

183 We investigated the relationship of circulating tumor cells (CTCs) in non-small cell lung ca

184 We evaluated the prognostic significance of circulating tumor cells (CTCs) in patients with esophage

185 merase chain reaction (RT-qPCR) detection of circulating tumor cells (CTCs) in patients with melanoma

186 Detection and characterization of rare circulating tumor cells (CTCs) in patients' blood is imp

187 We tested the hypothesis that circulating tumor cells (CTCs) in preoperative periphera

188 The detection of circulating tumor cells (CTCs) in the blood of cancer pa

189 rts that the association of neutrophils with circulating tumor cells (CTCs) in the blood of patients

190 elets have been shown to promote survival of circulating tumor cells (CTCs) in the bloodstream by con

191 tage detection and precise quantification of circulating tumor cells (CTCs) in the peripheral blood o

192 sion persists in metastatic lung nodules and circulating tumor cells (CTCs) in two mouse models of ma

193 R-V7) protein expression and localization on circulating tumor cells (CTCs) is a treatment-specific m

194 The identification and analysis of circulating tumor cells (CTCs) is an important goal for

195 Magnetic capture of circulating tumor cells (CTCs) is one of the most promis

196 port that elevated expression of each GEF in circulating tumor cells (CTCs) isolated from the periphe

197 The detection and analysis of circulating tumor cells (CTCs) may enable a broad range

198 Circulating tumor cells (CTCs) may have utility as surro

199 e metastases is challenging; hence, sampling circulating tumor cells (CTCs) may reveal drug-resistanc

200 h the bloodstream either as single migratory circulating tumor cells (CTCs) or as multicellular group

201 aimed to evaluate the relationships between circulating tumor cells (CTCs) or plasma cell-free DNA (

202 Circulating tumor cells (CTCs) play a fundamental role i

203 Circulating tumor cells (CTCs) provide the capacity for

204 The analysis of circulating tumor cells (CTCs) provides a means to colle

205 Analysis of circulating tumor cells (CTCs) provides real-time measur

206 Circulating tumor cells (CTCs) represent a surrogate bio

207 Circulating tumor cells (CTCs) shed from solid tumors ca

208 l lines, primary prostate cancer tissues and circulating tumor cells (CTCs) to investigate their role

209 Moreover, uPtDs NPs could target the in vivo circulating tumor cells (CTCs) to suppress TNBC lung met

210 Circulating tumor cells (CTCs) were detected in the hepa

211 We assessed circulating tumor cells (CTCs) with epithelial and mesen

212 gression-free survival (rPFS) and effects on circulating tumor cells (CTCs), bone biomarkers, serum p

213 A potential solution is to characterize circulating tumor cells (CTCs), but this requires overco

214 opic ultrasound (EUS) to count portal venous circulating tumor cells (CTCs), compared with paired per

215 We find that cultured circulating tumor cells (CTCs), derived from blood sampl

216 e of detecting common POC targets, including circulating tumor cells (CTCs), DNA/RNA, and curcumin, a

217 t of an efficient technique for detection of circulating tumor cells (CTCs), due to their significanc

218 nd metastatic disease, through the spread of circulating tumor cells (CTCs), is responsible for the m

219 are often easily accessible in the blood as circulating tumor cells (CTCs), making them ideal target

220 Measuring PD-L1 expression in circulating tumor cells (CTCs), may allow real-time moni

221 Circulating tumor cells (CTCs), which are prevalent in S

222 Additionally, deletion of miR-182 decreased circulating tumor cells (CTCs), while overexpression of

223 analysis of cancer cells in blood-so-called circulating tumor cells (CTCs)-may provide unprecedented

224 for detection, isolation, and enrichment of circulating tumor cells (CTCs)-rare cells that enter the

225 cancer cells is a new approach for detecting circulating tumor cells (CTCs).

226 gement diagnosis could be performed by using circulating tumor cells (CTCs).

227 for simultaneous isolation and detection of circulating tumor cells (CTCs).

228 el single cell analysis platforms focused on circulating tumor cells (CTCs).

229 Increased circulating tumor cells (CTCs; five or more CTCs per 7.5

230 Within an elaborate case study of circulating tumor cells derived from prostate cancer pat

231 were tested for the presence and quantity of circulating tumor cell-derived nucleases.

232 d has been an effective tool to perform rare Circulating Tumor Cells detection.

233 Clinical data on survival and circulating tumor cell DNA (ctDNA) concentrations were u

234 MT, however, is not required for metastasis: circulating tumor cells exhibit hybrid epithelial-mesenc

235 of upcoming biomarkers, including microRNA, circulating tumor cells, exosomes, and cell-free DNA, an

236 rker types, including circulating tumor DNA, circulating tumor cells, extracellular vesicles (exosome

237 e analysis of Sur biomarkers in exosomes and circulating tumor cells for a non-invasive liquid biopsy

238 ould be an effective tool to directly target circulating tumor cells for the prevention of prostate c

239 rous devices developed to isolate individual circulating tumor cells from blood, these devices are in

240 or splice variant 7 messenger RNA (AR-V7) in circulating tumor cells from men with advanced prostate

241 Detection of AR-V7 in circulating tumor cells from patients with castration-re

242 n and on-chip phenotypic characterization of circulating tumor cells from peripheral venous blood in

243 se-chain-reaction assay to evaluate AR-V7 in circulating tumor cells from prospectively enrolled pati

244 te early treatment of metastasis by clearing circulating tumor cells from vasculature.

245 hly sensitive microfluidic system to capture circulating tumor cells from whole blood of cancer patie

246 Further dissection of the circulating tumor cell gene signature identified signali

247 CTC transcriptomes, we discovered a unique "circulating tumor cell gene signature" that is distinct

248 tients with informative unfavorable baseline circulating tumor cells >= 5/7.5 mL of blood, 16 (59%) s

249 rs such as cancer antigen 15-3 (CA 15-3) and circulating tumor cells have been widely studied.

250 Detection of rare cells, such as circulating tumor cells, have many clinical applications

251 assay of circulating tumor DNA, CA 15-3, and circulating tumor cells in 30 women with metastatic brea

252 latory shear stress in cellular responses of circulating tumor cells in a physiologically relevant mo

253 In some applications (e.g., working with circulating tumor cells in blood), only a limited number

254 in metastatic capacity and in the number of circulating tumor cells in both the E2F1 and E2F2 knocko

255 label-free identification and measurement of circulating tumor cells in cancer research and disease m

256 y, OGX-427 treatment decreased the number of circulating tumor cells in patients with metastatic cast

257 it of reducing tumor size, PTX increased the circulating tumor cells in the blood and enhanced the me

258 er dormancy is evident from the detection of circulating tumor cells in the blood and tissue-residing

259 Circulating tumor cells in the blood of patients are bot

260 and this was associated with a reduction in circulating tumor cells in the E2F2 knockout.

261 markers such as cell-free nucleic acids and circulating tumor cells in the peripheral blood.

262 novehicle can also effectively eliminate the circulating tumor cells in vivo and inhibit development

263 ADT-sensitivity, and reduces the shedding of circulating tumor cells in vivo with significant shrinka

264 the survival and growth of metastasizing and circulating tumor cells in vivo.

265 specific cells from complex matrices (i.e., circulating tumor cells in whole blood).

266 ging of gastrointestinal tract, bladder, and circulating tumor cells (in vivo flow cytometry); and in

267 cells into the mouse leads to the release of circulating tumor cells into the vasculature, which seed

268 scoveries, challenges, and future trends for circulating tumor cell investigations, arguing that the

269 AR-V expression in patient tissues or circulating tumor cells is associated with resistance to

270 A platform for capture and release of circulating tumor cells is demonstrated by utilizing pol

271 Since hematogenous dissemination of circulating tumor cells is the major route of metastasis

272 In studies in vivo, we discovered that circulating tumor cells labeled with the nanohybrids gen

273 of fluid-based assays, notably, exosomes and circulating tumor cells (liquid biopsy), as tools for fu

274 od, 16 (59%) showed conversions to favorable circulating tumor cells < 5.

275 le of mechanotransduction in cancer, and how circulating tumor cells may be capable of continuously c

276 isrupt the HA machinery of primary tumor and circulating tumor cells may enhance the effectiveness of

277 To colonize distant sites, circulating tumor cells must destabilize the endothelial

278 In this model, circulating tumor cell numbers are significantly reduced

279 on, where active YAP increased the number of circulating tumor cells over time.

280 ng predictor of PFS, even in the presence of circulating tumor cells ( P = .004).

281 cific biomolecules, including nucleic acids, circulating tumor cells, proteins, antibodies, and extra

282 Circulating tumor cells provide a source of noninvasivel

283 ug assays with patient-derived cells such as circulating tumor cells requires manipulating small samp

284 Moreover, the observation that circulating tumor cells resemble the parental cell line,

285 In > 200 cancer cell lines and in primary circulating tumor cells, SETD1A expression correlates wi

286 vestigate small populations of cells such as circulating tumor cells shed from solid tumors and isola

287 ovides an important new tool for identifying circulating tumor cell subtypes.

288 nd to move collectively, forming clusters of circulating tumor cells that are key tumor-initiating ag

289 promise as an effective means to neutralize circulating tumor cells that enter blood with the potent

290 al utility of the SNARE with prostate cancer circulating tumor cells to demonstrate its ability to pe

291 ernalization, thus inhibiting the ability of circulating tumor cells to extravasate and colonize, lea

292 ells inhibited extravasation/colonization of circulating tumor cells to the lung and inhibited tumor

293 enrichment and molecular characterization of circulating tumor cells using peripheral venous blood in

294 mic alterations were identified; CA 15-3 and circulating tumor cells were detected in 21 of 27 women

295 s of tumor spread were measured serially and circulating tumor cells were detected via fluorescence m

296 CA 15-3 levels and numbers of circulating tumor cells were measured at identical time

297 Furthermore, circulating tumor cells were significantly reduced in tu

298 e metastasis by promoting the association of circulating tumor cells with blood cells to augment tumo

299 f the association of androgen receptor-V7 in circulating tumor cells with resistance to enzalutamide

300 Moreover, recent analyses suggest that circulating tumor cells within the vasculature often exi